Receptor Imaging(수용체 이미징)란 무엇입니까?
Receptor Imaging 수용체 이미징 - "Glucagonlike peptide-1 (GLP-1) receptor imaging, using radiolabeled exendin-4, was recently established for detecting insulinoma in patients with hyperinsulinemic hypoglycemia. [1] BackgroundCurrently, [18F] altanserin is the most frequently used PET-radioligand for serotonin2A (5-HT2A) receptor imaging in the human brain but has never been validated in dogs. [2] 77] and somatostatin-receptor imaging (OR 3. [3] This review summarizes some different strategies for expansion of radiolabeled probes for receptor imaging with a particular focus on the results from studies that have provided both in vitro and in vivo specific tumor targeting and compared their data for any correlation between two experiments. [4]"방사선 표지된 엑센딘-4를 사용하는 글루카곤 유사 펩티드-1(GLP-1) 수용체 영상은 고인슐린혈증 저혈당증 환자에서 인슐린종을 검출하기 위해 최근에 확립되었습니다. [1] 배경 현재 [18F] 알탄세린은 인간 뇌에서 세로토닌2A(5-HT2A) 수용체 영상화를 위해 가장 자주 사용되는 PET-방사선 리간드이지만 개에서 검증된 적이 없습니다. [2] 77] 및 소마토스타틴 수용체 영상화(OR 3. [3] 이 검토는 체외 및 생체 내 특정 종양 표적화를 제공한 연구 결과에 특히 초점을 두고 수용체 이미징을 위한 방사성 표지된 프로브의 확장을 위한 몇 가지 다른 전략을 요약하고 두 실험 간의 상관 관계에 대한 데이터를 비교했습니다. [4]
positron emission tomography 양전자 방출 단층 촬영
This is particularly evident with esthesioneuroblastoma, with computed tomography and magnetic resonance imaging defining the anatomic extent of the tumor, whereas somatostatin receptor imaging, particularly with gallium-68 DOTATATE positron emission tomography/computed tomography, is used to assess the presence of metastatic disease for staging purposes as well as in the surveillance for tumor recurrence. [1] Dopaminergic neurotransmission can best be assessed using positron emission tomography (PET) or single-photon emission computed tomography (SPECT), with tracers available for dopamine synthesis capacity, dopamine D1 and D2 receptor imaging, and the assessment of transporter availability. [2] We report an efficient protocol for the radiosynthesis of diastereomerically pure (E)-[11 C]ABP688, a positron emission tomography (PET) tracer for metabotropic glutamate type 5 (mGlu5) receptor imaging. [3] Receptor imaging with positron emission tomography (PET) provides a non-invasive method for monitoring GLP-1R expression. [4] Furthermore, the role of somatostatin receptor imaging through single-photon emission computed tomography (SPECT) and positron emission tomography (PET) probes, with reference to their potential therapeutic implications, was examined in the peculiar context. [5] 312 diagnostic examinations were performed: Endoscopic ultrasonography (EUS, n=59, sensitivity 70%), magnetic resonance imaging (n=33, sensitivity 58%), computed tomography (CT, n=55, sensitivity 47%), transabdominal US (n=45, sensitivity 40%), somatostatin receptor imaging (n=17, sensitivity 29%), 18F-FDG positron emission tomography/CT (n=1, negative), percutaneous transhepatic venous sampling (n=10, sensitivity 90%), arterial stimulation venous sampling (n=20, sensitivity 65%) and intra-operative US (n=72, sensitivity 89%). [6]이것은 종양의 해부학적 범위를 정의하는 컴퓨터 단층촬영과 자기공명영상촬영을 통해 특히 갈륨-68 DOTATATE 양전자방출단층촬영/컴퓨터 단층촬영을 사용하는 소마토스타틴 수용체 영상을 사용하여 전이성 질환의 존재를 평가하는 데 사용됩니다. 종양 재발에 대한 감시뿐만 아니라 병기 결정 목적. [1] 도파민성 신경전달은 양전자 방출 단층 촬영(PET) 또는 단일 광자 방출 컴퓨터 단층 촬영(SPECT)을 사용하여 가장 잘 평가할 수 있으며, 추적자는 도파민 합성 능력, 도파민 D1 및 D2 수용체 영상화, 수송체 이용 가능성 평가에 사용할 수 있습니다. [2] 우리는 대사성 글루타메이트 5형(mGlu5) 수용체 영상화를 위한 양전자 방출 단층촬영(PET) 추적자인 부분입체이성질체적으로 순수한(E)-[11 C]ABP688의 방사선 합성을 위한 효율적인 프로토콜을 보고합니다. [3] nan [4] nan [5] nan [6]
Somatostatin Receptor Imaging 소마토스타틴 수용체 이미징
Eleven patients with lung tumors and 4 with pulmonary infections also had additional somatostatin receptor imaging (99mTc-HYNIC-TOC SPECT/CT or 68Ga-DOTATATE PET/CT). [1] Well-differentiated morphology, Ki-67 <50% and positive somatostatin receptor imaging were independently associated with prolonged survival. [2] Visual PET scans using 18F-FDG and somatostatin receptor imaging agents are both used in imaging of neuroendocrine neoplasms (NENs). [3] Combining evaluation for blood and urinary catecholamine levels, somatostatin receptor imaging, and iodine-131 metaiodobenzylguanidine scintigraphy, he was confirmed with the diagnosis of cardiac paraganglioma with blood supply from the right coronary artery identified via angiography. [4] 77/4), negative somatostatin receptor imaging (WA 2. [5] Somatostatin receptor imaging, heavily utilized in neuroendocrine oncology, may also have utility in the diagnosis of other neoplasms and raises the possibility of potential therapeutic options. [6] Somatostatin receptor imaging was positive in 14 of 15 investigated cases. [7] Receptor expression of the total tumor burden may be visualized by somatostatin receptor imaging, e. [8] Radiolabeled metaiodobenzylguanidine (MIBG) and somatostatin receptor imaging have laid the groundwork for use of these radiopharmaceuticals as theranostic agents. [9] ABSTRACT Patients with unresectable or metastasized neuroendocrine tumors are assumed eligible for PRRT (peptide receptor radionuclide therapy) with 177Lu-HA-DOTATATE if tumor uptake on somatostatin receptor imaging is higher than normal liver tissue. [10] This is particularly evident with esthesioneuroblastoma, with computed tomography and magnetic resonance imaging defining the anatomic extent of the tumor, whereas somatostatin receptor imaging, particularly with gallium-68 DOTATATE positron emission tomography/computed tomography, is used to assess the presence of metastatic disease for staging purposes as well as in the surveillance for tumor recurrence. [11] This study aimed to assess the usefulness of somatostatin receptor imaging, called 68Ga-DOTATOC PET/CT, in the management of patients with TIO. [12] The most common radiotracers used in clinical practice can detect increased energy metabolism (FDG), macrophage number (somatostatin receptor imaging), the intensity of cell proliferation in the area (labeled choline), and microcalcifications (fluoride imaging). [13] While the Food and Drug Administration has approved the use of 68Ga-DOTATATE as a radiopharmaceutical for somatostatin receptor imaging, the use of its radiotherapeutic counterpart still needs approval beyond gastroenteropancreatic neuroendocrine tumors. [14] Our case highlights the importance of further research into the use of PRRT in patients with a Ki-67 <55% and uptake on somatostatin receptor imaging. [15] Some patients had positive results on somatostatin receptor imaging, but none had positive results on 131I-metaiiodo-benzylguanidine (131I-MIBG). [16] Blood and urine catecholamines were elevated, somatostatin receptor imaging was positive, and the diagnosis of PGL was clear. [17] However, a clinical dilemma often arises in the selection of TRT, especially when a patient can be treated with either type of therapy based on eligibility by MIBG and somatostatin receptor imaging. [18] Accordingly, its role in detecting sites of disease is compromised in an era when somatostatin receptor imaging, combined with FDG PET/CT for higher-grade NEN, has become a routine part of the diagnostic paradigm, at least in some parts of the world [9]. [19] Peptide receptor radionuclide therapy (PRRT) is an established treatment for grade 1 and 2 gastroenteropancreatic neuroendocrine tumors with an increased uptake on somatostatin receptor imaging (SRI). [20] Such therapy could theoretically lead to misinterpretation of somatostatin receptor imaging with 68Ga-DOTATATE PET/CT by interfering with tracer–receptor binding. [21] Biodistribution and imaging results provide basic information for the further study of somatostatin receptor imaging in neuroendocrine tumors. [22] We recommend that, in addition to the conventional radiological investigations, Tc-99m-OCT scan, or other somatostatin receptor imaging (SSR) is a mandate for better and accurate staging of patients with NETs. [23] Furthermore, the role of somatostatin receptor imaging through single-photon emission computed tomography (SPECT) and positron emission tomography (PET) probes, with reference to their potential therapeutic implications, was examined in the peculiar context. [24] We recommend that, in addition to the conventional radiological investigations, Tc-99m-OCT scan, or other somatostatin receptor imaging (SSR) is a mandate for better and accurate staging of patients with NETs. [25] The diagnosis of orbital metastatic NEN was made on somatostatin receptor imaging and confirmed on a dedicated MRI of orbits. [26] Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. [27] Studies exploring the role of somatostatin receptor imaging and receptor-specific therapies in patients with parathyroid carcinomas are needed. [28] In one patient, preoperative abdominal enhanced volume perfusion computed tomography (CT), somatostatin receptor imaging and 99mTc-HYNIC-TOC SPECT/CT revealed a mass with a rich blood supply anterior to the duodenum. [29] 312 diagnostic examinations were performed: Endoscopic ultrasonography (EUS, n=59, sensitivity 70%), magnetic resonance imaging (n=33, sensitivity 58%), computed tomography (CT, n=55, sensitivity 47%), transabdominal US (n=45, sensitivity 40%), somatostatin receptor imaging (n=17, sensitivity 29%), 18F-FDG positron emission tomography/CT (n=1, negative), percutaneous transhepatic venous sampling (n=10, sensitivity 90%), arterial stimulation venous sampling (n=20, sensitivity 65%) and intra-operative US (n=72, sensitivity 89%). [30] In well differentiated neuroendocrine tumours, somatostatin receptor imaging, as one of the first examples of receptor targeted imaging in humans, plays an important role in the diagnostic work-up of these patients. [31] Somatostatin receptor imaging and therapy utilizes the SSTR expression. [32] Somatostatin receptor imaging plays an important role in the diagnosis of spreading and in the planning of therapy. [33] Ga-DOTA-peptide (Ga-DOTATATE/-TOC/-NOC) PET is the current standard for somatostatin receptor imaging in neuroendocrine tumour (NET) patients, but suffers from practical, regulatory and economical barriers associated with Ge/Ga-generators [1, 2]. [34] Somatostatin receptor imaging has emerged as imaging of the choice in the localization of the causative tumors in new patients with clinical diagnosis of TIO. [35] Another imaging modality is somatostatin receptor imaging with PET/CT which can be used especially when 18F-FDG PET/CT is nondiagnostic. [36] Somatostatin receptor imaging has previously been performed with a gamma camera using [111In]In or [99mTc]Tc-labelled compounds, while [68Ga]Ga-labelled compounds and PET/CT imaging has recently become the gold standard for the diagnosis and management of these tumors. [37]폐 종양이 있는 11명의 환자와 폐 감염이 있는 4명의 환자도 추가로 소마토스타틴 수용체 영상(99mTc-HYNIC-TOC SPECT/CT 또는 68Ga-DOTATATE PET/CT)을 받았습니다. [1] 잘 분화된 형태, Ki-67 <50% 및 양성 소마토스타틴 수용체 영상은 독립적으로 연장된 생존과 관련이 있었습니다. [2] 18F-FDG 및 소마토스타틴 수용체 영상화제를 사용하는 시각적 PET 스캔은 모두 신경내분비 신생물(NEN)의 영상화에 사용됩니다. [3] nan [4] nan [5] nan [6] nan [7] nan [8] nan [9] nan [10] 이것은 종양의 해부학적 범위를 정의하는 컴퓨터 단층촬영과 자기공명영상촬영을 통해 특히 갈륨-68 DOTATATE 양전자방출단층촬영/컴퓨터 단층촬영을 사용하는 소마토스타틴 수용체 영상을 사용하여 전이성 질환의 존재를 평가하는 데 사용됩니다. 종양 재발에 대한 감시뿐만 아니라 병기 결정 목적. [11] nan [12] nan [13] nan [14] nan [15] nan [16] nan [17] nan [18] nan [19] 펩티드 수용체 방사성 핵종 요법(PRRT)은 소마토스타틴 수용체 영상화(SRI)에 대한 흡수가 증가된 1등급 및 2등급 위장 췌장 신경내분비 종양에 대한 확립된 치료법입니다. [20] 이러한 치료는 이론적으로 추적자-수용체 결합을 방해하여 68Ga-DOTATATE PET/CT를 사용한 소마토스타틴 수용체 영상의 잘못된 해석으로 이어질 수 있습니다. [21] nan [22] nan [23] nan [24] nan [25] nan [26] nan [27] nan [28] nan [29] nan [30] nan [31] nan [32] nan [33] nan [34] nan [35] nan [36] nan [37]
1 Receptor Imaging
Sigma-1 receptor imaging probes for determining the expression levels are desirable for diagnoses of various diseases and companion diagnoses of therapeutic agents targeting the sigma-1 receptor. [1] In conclusion, our metabolic study, in particular the high fractions of unchanged radioligand in plasma, confirms the suitability of (S)-[18F]1 as PET radioligand for sigma-1 receptor imaging. [2]발현 수준을 결정하기 위한 시그마-1 수용체 영상 프로브는 시그마-1 수용체를 표적으로 하는 치료제의 다양한 질병의 진단 및 동반 진단에 바람직하다. [1] 결론적으로, 우리의 대사 연구, 특히 혈장에서 변하지 않은 방사성 리간드의 높은 분율은 시그마-1 수용체 영상화를 위한 PET 방사성 리간드로서 (S)-[18F]1의 적합성을 확인합니다. [2]
V1a Receptor Imaging V1a 수용체 이미징
OBJECTIVES To enable non-invasive real-time quantification of vasopressin 1A (V1A) receptors in peripheral organs, we sought to develop a suitable PET probe that would allow specific and selective V1A receptor imaging in vitro and in vivo. [1] Objectives To enable non-invasive real-time quantification of vasopressin 1A (V1A) receptors in peripheral organs, we sought to develop a suitable PET probe that would allow specific and selective V1A receptor imaging in vitro and in vivo. [2]목표 말초 기관에서 바소프레신 1A(V1A) 수용체의 비침습적 실시간 정량화를 가능하게 하기 위해 우리는 시험관 내 및 생체 내에서 특이적이고 선택적인 V1A 수용체 이미징을 허용하는 적합한 PET 프로브를 개발하고자 했습니다. [1] 목적 말초 기관에서 바소프레신 1A(V1A) 수용체의 비침습적 실시간 정량화를 가능하게 하기 위해, 우리는 시험관 내 및 생체 내에서 특이적이고 선택적인 V1A 수용체 이미징을 허용하는 적합한 PET 프로브를 개발하고자 했습니다. [2]
receptor imaging agent 수용체 이미징 에이전트
Visual PET scans using 18F-FDG and somatostatin receptor imaging agents are both used in imaging of neuroendocrine neoplasms (NENs). [1] SPECT imaging was performed in H460 xenograft mouse model, [ 99m Tc]TcAMD3465 showed comparable tumor uptake and a significantly high tumor-to-background ratio, suggesting potential utility of [ 99m Tc]TcAMD3465 as a CXCR4 receptor imaging agent. [2] Currently, PET imaging agents that target macrophages can be roughly classified into metabolic, enzyme, cytokine, and receptor imaging agents. [3]18F-FDG 및 소마토스타틴 수용체 영상화제를 사용하는 시각적 PET 스캔은 모두 신경내분비 신생물(NEN)의 영상화에 사용됩니다. [1] SPECT 영상화는 H460 이종이식 마우스 모델에서 수행되었으며, [ 99m Tc]TcAMD3465는 유사한 종양 흡수 및 상당히 높은 종양 대 배경 비율을 보여 CXCR4 수용체 영상화제로서 [ 99m Tc]TcAMD3465의 잠재적 유용성을 시사합니다. [2] 현재 대식세포를 표적으로 하는 PET 영상화제는 크게 대사성, 효소, 사이토카인, 수용체 영상화제로 분류할 수 있다. [3]